While a DNA integration approach for CAH using conventional transposable elements could allow persistence of expression of the newly introduced CYP21A2, the site of integration of the transposable element is random and would not allow for physiological control of gene expression through transcriptional regulation under the native CYP21A2 promoter. The gene discussed is CYP21A2; the disease is congenital adrenal hyperplasia.